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ABSTRACT
Background:	Bariatric	surgery	reduces	cardiovascular	events	and	mortality	risk	in	obese	individuals.	However,	it
is	unclear	whether	diabetes	modiﬁed	this	eﬀect.	We	aimed	to	examine	mortality,	cardiovascular	and	cancer	risk
following	bariatric	surgery	in	adults	with	and	without	pre-exisAng	diabetes	and	compare	mortality	risk	to	the
general	populaAon.
Methods:	Using	mortality	linked-Hospital	Episodes	StaAsAcs	(2006-2014)	from	England,	we	examined	risk	of
death,	myocardial	infarcAon,	stroke,	unstable	angina,	heart	failure,	and	cancer	following	bariatric	surgery;	and
compared	risk	of	death	in	people	undergoing	bariatric	to	mortality	rates	of	the	general	populaAon.
Results:	Of	the	35,887	people	undergoing	bariatric	surgery,	9,175	(25.6%)	had	pre-exisAng	diabetes.	During	a
mean	follow-up	of	5.3	years,	801	people	died,	of	whom	293	(36.6%)	had	pre-exisAng	diabetes.	The	risk	of	all-
cause	mortality	in	people	with	diabetes	was	26%	higher	compared	to	those	without	(adjusted	hazard	raAo
(aHR):	1.26,	95%CI:	1.08-1.46)	whilst	cancer	was	21%	higher	(aHR	1.21,	1.14-1.77).	ParAcipants	with	diabetes
before	bariatric	surgery	had	increased	risk	for	post-surgery	cardiovascular	events	compared	to	paAents	without
pre-exisAng	diabetes	(aHR	myocardial	infarcAon:	2.08,	1.42-3.05;	unstable	angina:	1.80,	1.29-2.52;	stroke:	1.61,
1.18-2.19;	heart	failure:	1.42,	1.14-1.77).	Compared	to	the	general	populaAon,	age-standardised	mortality	rate
raAo	was	1.70	(1.52-1.91)	and	1.35	(1.23-1.48)	in	people	with	and	without	pre-exisAng	diabetes,	respecAvely.
Conclusions:	In	paAents	who	underwent	bariatric	surgery	with	pre-exisAng	diabetes,	the	risk	of	death,
cardiovascular	events,	and	cancer	was	higher	compared	to	those	without	diabetes,	whose	mortality	risk	a]er
surgery	sAll	remains	35%	higher	compared	to	that	of	the	general	populaAon.
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Highlights
PaAents	with	diabetes	carry	a	residual	risk	of	cardiovascular,	cancer,	and	mortality	events	a]er	bariatric
surgery:	compared	to	paAents	without	diabetes,	the	risk	is	26%	higher	of	all-cause	mortality,	21%	higher
for	cancer;	42%	higher	for	heart	failure;	61%	higher	for	stroke;	and	double	for	myocardial	infarcAon.
	
The	risk	of	death	a]er	bariatric	surgery	remains	higher	also	in	paAents	without	diabetes	compared	to
subjects	of	same	age	from	the	general	populaAon.
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	INTRODUCTION
The	latest	global	esAmates	from	2016	indicate	that	obesity	is	rapidly	increasing,	with	over	650	million	obese
people	worldwide.1	In	2014,	the	prevalence	of	obesity	in	the	UK	and	U.S.	was	26%2	and	36.5%,	respecAvely.3
Bariatric	surgery	is	an	eﬀecAve	treatment	for	weight	loss	in	severe	cases	of	obesity4,5	and	has	been	shown	to
reduce	the	risk	of	cardiovascular	disease	(CVD)	and	mortality	in	obese	people.6-9	Results	from	the	Swedish
Obese	Subjects	(SOS)	study	also	demonstrated	a	reducAon	in	the	incidence	of	type	2	diabetes	a]er	bariatric
surgery	and	improvements	in	glycaemic	control.4	More	recent	data	from	Sweden	show	reducAon	in	all-cause
mortality	and	cardiovascular	events	a]er	bariatric	surgery	compared	to	obese	paAents	with	diabetes	who	did
not	undergo	surgery.10	It	is	unclear,	however,	whether	the	presence	of	diabetes	before	surgery	alters	the
associaAon	of	bariatric	surgery	with	cardiovascular	and	mortality	outcomes.	The	Longitudinal	Assessment	of
Bariatric	Surgery	-	1	(LABS-1)	study	found	no	independent	associaAon	of	diabetes	on	a	composite	outcome	at
30	days	(including	death,	deep	vein	thrombosis,	pulmonary	embolism,	any	intervenAon	and	hospital	stay)	in
the	presence	of	other	risk	factors.11	In	contrast,	data	from	the	Italian	Society	of	Obesity	Surgery	(SICOB)
including	13,431	paAents,	found	a	low	risk	of	early	mortality	following	a	bariatric	procedure,	although	the	risk
in	paAents	with	diabetes	was	double	that	of	the	risk	in	paAents	without	diabetes.12	InternaAonal	guidelines
recommend	bariatric	surgery	for	adults	with	a	body	mass	index	(BMI)	of	40kg/m2	or	more,	or	between
35kg/m2-40kg/m2	or	greater	in	the	presence	of	other	signiﬁcant	diseases	including	type	2	diabetes.13,	14,15	In
light	of	these	guidelines	and	the	limited	and	inconsistent	previous	ﬁndings	on	mortality	outcomes	a]er
bariatric	surgery	in	presence	of	pre-exisAng	diabetes,	we	aimed	to	examine	all-cause	and	cardiovascular
mortality,	incidence	of	cardiovascular	and	cancer	events,	following	bariatric	surgery	in	adults	with	and	without
pre-exisAng	diabetes	in	England	and	to	esAmate	the	risk	of	all-cause	mortality	following	bariatric	surgery	in
people	with	and	without	diabetes	compared	to	the	general	populaAon.
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METHODS
	
Data	source,	study	popula=on	and	exposure	deﬁni=on
The	Hospital	Episodes	StaAsAcs	(HES)	dataset	contains	details	of	all	emergency	and	elecAve	inpaAent
admissions	funded	by	the	NaAonal	Health	Service	(NHS)	in	England.	Diagnoses	and	procedures	are	coded	using
the	InternaAonal	ClassiﬁcaAon	of	Diseases	10th	revision	(ICD-10)	and	the	Oﬃce	of	PopulaAon	Census	and
Surveys	V.4	(OPCS-4),	respecAvely.	The	Oﬃce	for	NaAonal	StaAsAcs	(ONS)	mortality	dataset	contains	the	date
and	cause	of	death	(coded	using	ICD-10)	for	all	deaths	registered	in	England.	This	longitudinal	cohort	analysis
made	use	of	the	linked	HES-ONS	mortality	data	to	idenAfy	all	adult	paAents	resident	in	England	undergoing
bariatric	surgery	procedures	from	April	2006	to	March	2014	using	the	OPCS-4	codes.	We	considered	a
parAcipant	as	having	bariatric	surgery	if	any	code	from	the	bariatric	surgery	code	list	appeared	as	the	primary
procedure	code	in	the	paAents’	records	in	addiAon	to	the	ICD-10	code	for	obesity	(E66)	as	their	primary
diagnosis	to	keep	our	exposure	deﬁniAon	as	speciﬁc	as	possible	(Supplementary	Table	S1).	Each	parAcipant
entered	the	study	on	the	date	of	admission	for	bariatric	surgery	a]er	1st	April	2006	and	was	censored	at	the
date	of	the	outcome	of	interest	or	the	end	of	the	follow-up	i.e.	1st	April	2014.	PaAents	with	baseline
cardiovascular	disease	or	gastric	cancer	were	excluded	from	the	analysis.	Pre-exisAng	diabetes	was	deﬁned	by
ICD-10	codes	E10-E14	on	or	before	the	index	date.
	
Main	outcome	measures
The	main	outcomes	assessed	in	this	study	were	all-cause	mortality	and	CVD	mortality.	InformaAon	on	in-
hospital	deaths	was	extracted	from	`discharge	method’	informaAon	in	HES,	which	was	further	supplemented	by
ONS	linkage.	All	other	deaths	were	extracted	from	ONS.	The	cause	of	death	was	considered	to	be
cardiovascular	if	the	underlying	cause	of	death	was	a	cardiovascular	event	(Supplementary	Table	S2).	We	also
assessed	the	incidence	of	cardiovascular	events	including	myocardial	infarcAon	(MI),	unstable	angina,	stroke,
heart	failure	and	cancer	(code	lists:	Supplementary	Table	S1).	Lastly,	we	assessed	mortality	rates	in	people	with
and	without	pre-exisAng	diabetes undergoing bariatric surgery compared to the UK	general	populaAon.
	
Sta=s=cal	Analysis
ParAcipant	characterisAcs	were	described	using	proporAons	and	were	compared	between	people	with	and
without	pre-exisAng	diabetes	using	chi-squared	tests.	Average	follow-up	Ame	overall	and	by	diabetes	status
was	calculated.	Time-to-event	for	all-cause	mortality,	cardiovascular	mortality,	and	incidence	of	MI,	unstable
angina,	stroke,	heart	failure,	and	cancer	were	compared	between	people	with	and	without	pre-exisAng
diabetes	using	Kaplan-Meier	survival	curves	and	survival	distribuAons	were	compared	using	a	log-rank	test.	Cox
proporAonal	hazards	models	were	used	to	calculate	hazard	raAos	(HR)	and	95%	CIs	comparing	people	with	and
without	pre-exisAng	diabetes,	adjusAng	for	age,	sex,	index	of	mulAple	deprivaAon	(IMD)	score,	ethnicity,
geographic	region,	procedure	type,	and	Charlson	comorbidity	index	(an	index	to	deﬁne	comorbidiAes	in
paAents)	modiﬁed	to	exclude	pre-exisAng	diabetes	and	eﬀect	modiﬁcaAon	by	procedure	type	was	also
assessed.	ProporAonal	hazards	assumpAon	was	checked	using	Schoenfeld	residuals.	Risk	for	all-cause	mortality
at	30	days	was	esAmated	using	the	same	method	as	above.	Lastly,	we	used	the	mortality	data	straAﬁed	by	age
for	England	and	Wales	in	2015	(hips://www.ons.gov.uk/)	and	corresponding	events	and	person-years	in	our
dataset	to	esAmate	with	negaAve	binomial	regression	all-cause	mortality	rate	raAo	following	bariatric	surgery	in
people	with	and	without	pre-exisAng	diabetes	compared	to	the	general	populaAon.
	
Sensi=vity	Analysis
A	restricted	deﬁniAon	of	bariatric	surgery	was	used	including	codes	only	for	primary	operaAons
(Supplementary	Table	S2)	and	HR	and	mortality	rate	raAo	were	recalculated	as	parAcipants	with
revision/secondary	operaAons	may	be	at	a	higher	risk	of	adverse	events	due	to	the	revision	of	surgery.	Lastly,	a
sensiAvity	analysis	restricted	the	deﬁniAon	of	bariatric	surgery	to	only	include	codes	exclusively	used	for
bariatric	surgery	was	also	performed	(Supplementary	Table	S2).
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	RESULTS 
	
Par=cipant	characteris=cs
A	total	of	38,060	parAcipants	underwent	a	bariatric	surgery	procedure	between	April	2006	and	March	2014.
A]er	excluding	parAcipants	with	baseline	CVD,	gastric	cancer	or	gastric	bubble/balloon	procedure	(n=1,552)
and	missing	informaAon	on	age,	sex	or	residence	recorded	as	outside	of	England	(n=634),	35,887	parAcipants
remained,	of	which	9,175	(25.6%)	had	a	record	of	diabetes	at	the	Ame	of	bariatric	surgery.	Approximately	85%
of	the	bariatric	surgery	procedures	were	performed	in	parAcipants	aged	between	30	to	59	years	(Table	1).	The
proporAon	of	women	with	pre-exisAng	diabetes	undergoing	bariatric	surgery	was	slightly	lower	compared
those	without	diabetes	(68.1%	vs.	80.7%,	respecAvely)	and	31.0%	paAents	undergoing	bariatric	surgery	were
from	the	most	deprived	areas	compared	to	the	10.6%	from	the	least	deprived	areas.	People	with	pre-exisAng
diabetes	had	higher	Charlson	comorbidity	score	compared	to	people	without	diabetes	(4.2%	people	in	the
diabetes	group	with	Charlson	score	≥5	vs.	1.6%	in	people	without	diabetes).	Bypass	procedures	consAtuted	half
of	the	total	bariatric	procedures	(Supplementary	Table	S3);	however,	people	with	pre-exisAng	diabetes	had	a
higher	proporAon	of	bypass	procedure	and	lower	proporAon	of	gastric	banding	compared	to	people	without
diabetes	(55.2%	vs.	50.1%	bypass	and	19.9%	vs.	24.1%	gastric	banding,	respecAvely).
	
All-cause	and	cardiovascular	mortality
During	a	mean	follow-up	of	5.3	years	(standard	deviaAon,	2.0	years),	there	were	801	deaths	of	which	293
(36.6%)	were	in	people	with	pre-exisAng	diabetes	and	508	(63.4%)	in	people	without.	There	was	no	staAsAcally
signiﬁcant	diﬀerence	in	the	30-day	mortality	following	bariatric	surgery	by	diabetes	status	(adjusted	HR
comparing	people	with	diabetes	to	without	diabetes:	1.58,	95%	CI	0.90-2.77).	In	people	with	pre-exisAng
diabetes,	the	incidence	for	all-cause	mortality	was	6.3	per	1,000	person-years	(95%	CI	5.6-7.1)	compared	to	3.5
per	1,000	person-years	(95%	CI	3.2-3.8)	in	people	without	(Supplementary	Figure	S1).	For	long-term	mortality,
Kaplan-Meier	curves	revealed	a	greater	mortality	risk	in	people	with	pre-exisAng	diabetes	compared	to	those
without	(p<0.001)	(Figure	1).	A]er	adjusAng	for	age,	sex,	IMD	score,	ethnicity,	geographic	region,	Charlson
comorbidity	index	and	procedure	type,	the	risk	of	all-cause	mortality	in	people	with	pre-exisAng	diabetes	was
26%	higher	compared	to	those	without	(HR	1.26,	95%	CI	1.08-1.46)	(Figure	2).	There	was	no	interacAon	in	the
associaAon	between	diabetes	status	and	mortality	by	procedure	type	(p	for	interacAon=0.344).	There	were	only
50	CVD	deaths	of	which	16	(32.0%)	were	in	the	diabetes	group.	Further	mulAvariable	analyses	were	not	carried
out	in	this	cohort,	due	to	the	small	number	of	events	in	the	diabetes	group.
	
Cardiovascular	events	and	cancer
The	incidence	ranged	from	0.3	per	1,000	person-years	and	1.5	per	1,000	person-years	for	MI	to	5.0	per	1,000
person-years	and	8.4	per	1,000	person-years	for	cancer	in	people	with	and	without	pre-exisAng	diabetes
respecAvely	(Supplementary	Figure	S1).		Of	the	121	incident	MIs,	71	(58.7%)	were	reported	in	people	with	pre-
exisAng	diabetes.	In	the	mulAvariable	analysis,	diabetes	was	associated	with	over	two-fold	increase	in	the	risk
of	an	MI	a]er	bariatric	surgery	compared	to	those	without	(HR	2.08,	95%	CI	1.42-3.05)	(Figure	2).	Diabetes	was
also	associated	with	an	increased	risk	of	unstable	angina	(69	events	in	people	with	pre-exisAng	diabetes	vs	87
in	people	without,	HR	1.80,	95%	CI	1.29-2.52).	Similarly,	people	with	pre-exisAng	diabetes	were	more	likely	to
have	a	stroke	compared	to	those	without	(77	vs	114	events,	respecAvely;	HR	1.61,	95%	CI	1.18-2.19).	The	risk	of
heart	failure	a]er	bariatric	surgery	was	higher	in	people	with	pre-exisAng	diabetes	compared	to	people	without
(153	vs	207	events	respecAvely;	HR	1.42,	95%	CI	1.14-1.77).	Lastly,	1,092	individuals	developed	cancer	during
the	follow-up,	of	whom	379	(34.7%)	had	pre-exisAng	diabetes.	The	risk	of	cancer	was	21%	higher	in	the	people
with	pre-exisAng	diabetes	compared	to	people	without	(HR	1.21,	95%	CI	1.07-1.38)	(Figure	2).
	
Mortality	compared	to	the	general	popula=on
The	age-speciﬁc	mortality	rates	were	higher	in	the	diabetes	group	compared	to	the	general	populaAon	for
younger	ages	with	progressively	lower	diﬀerences	in	older	people	(Supplementary	Figure	S2;	Figure	3).	People
without	pre-exisAng	diabetes	who	underwent	bariatric	surgery	had	a	35%	increased	risk	of	all-cause	mortality
compared	to	the	general	populaAon	(age-standardised	mortality	rate	raAo:	1.35,	95%	CI	1.23-1.48;	Figure	3).	In
comparison,	people	with	pre-exisAng	diabetes	and	bariatric	surgery	had	a	70%	increased	risk	of	all-cause
mortality	compared	(age-standardised	mortality	rate	raAo:	1.70,	95%	CI	1.52-1.91)	(Figure	3).
	
Sensi=vity	Analyses
The	esAmates	remained	similar	to	the	main	analysis	when	the	deﬁniAon	of	bariatric	surgery	was	restricted	to
only	include	primary	procedure	codes.	Similarly,	when	restricAng	the	deﬁniAon	of	bariatric	surgery	to	only
codes	exclusively	used	for	bariatric	surgery,	the	risk	of	all-cause	mortality	in	the	diabetes	group	was	33%	higher
(HR	1.33,	95%	CI	1.10-1.60)	(Supplementary	Table	S4).
1
	
	
1
	
DISCUSSION
	
Principal	Findings
In	this	large	populaAon-based	study,	we	found	the	risk	of	all-cause	mortality	to	be	26%	higher	a]er	bariatric
surgery	in	people	with	pre-exisAng	diabetes	compared	to	those	without	diabetes.	The	risk	of	all	cardiovascular
outcomes	including	MI,	stroke,	unstable	angina,	and	heart	failure	was	also	greater	in	adults	with	pre-exisAng
diabetes,	with	the	risk	of	MI	being	over	twice	as	high	in	adults	with	pre-exisAng	diabetes	compared	to	people
without	diabetes.	Similarly,	the	rate	of	cancer	was	21%	higher	following	bariatric	surgery	in	people	with	pre-
exisAng	diabetes	compared	with	people	without.	Notably,	the	risk	of	death	following	bariatric	surgery	remained
higher	in	paAents	without	diabetes	when	compared	to	that	of	the	general	populaAon.
	Strengths	and	limita=ons
To	our	knowledge,	this	is	the	largest	study	to	comprehensively	examine	the	risk	of	mortality	and	other
complicaAons	following	bariatric	surgery	by	diabetes	status.	Data	from	HES	captured	diagnoses,	procedures,
and	other	comorbidiAes	for	all	hospital	admissions	in	England	and	mortality	data	were	further	conﬁrmed
through	linkage	with	ONS,	hence	the	outcome	ascertainment	in	our	study	was	robust.	However,	these	data	are
primarily	collected	for	administraAve	and	ﬁnancial	purposes.	Therefore,	we	did	not	have	informaAon	on
baseline	BMI	or	the	change	in	BMI	a]er	bariatric	surgery	or	HbA1c	before	surgery.	Nevertheless,	in	the	UK,
unAl	2014	bariatric	surgery	was	only	oﬀered	to	people	with	a	BMI	of	40kg/m2	or	more,	or	between	35kg/m2-
40kg/m2	or	greater	in	the	presence	of	other	signiﬁcant	disease	including	diabetes.13		A	study	including	756
paAents	undergoing	bariatric	surgery	at	Brigham	and	Women’s	Hospital,	Boston	found	the	mean	BMI	to	be	47
(standard	deviaAon,	6.8)	and	47	(7.3)	in	people	with	and	without	diabetes	and	no	staAsAcally	signiﬁcant
diﬀerence	between	the	two	groups.16	Therefore,	we	believe	the	BMI	of	parAcipants	was	at	least	35kg/m2.
AddiAonally,	due	to	the	nature	of	data	collecAon	for	HES,	we	also	did	not	have	informaAon	on	duraAon	and
severity	of	diabetes	and	glycaemic	control	before	and	a]er	bariatric	surgery	and	residual	confounding	may	be
present.	Furthermore,	owing	to	similar	limitaAons	of	data	recording,	we	could	not	further	straAfy	the	group
without	diabetes	into	euglycaemia	and	prediabetes.	We	included	all	codes	for	diabetes	rather	than	speciﬁc	type
2	diabetes	as	the	type	of	diabetes	is	not	very	well	phenotyped	in	HES	and	some	paAents	have	codes	for	both
type	1	and	type	2	over	Ame.17	Nevertheless,	around	85%	of	the	parAcipants	were	idenAﬁed	as	having	type	2
diabetes.17			Lastly, when comparing age-specific mortality rates with the general population,	we	could	only
include	age	35-74	as	the	number	of	events	in	other	age	groups	was	either	very	small	or	nil.
	
Comparison	with	current	literature
We	found	that,	in	spite	of	no	signiﬁcant	diﬀerence	in	30-day	mortality,	the	risk	of	long-term	mortality	and	CVD
outcomes	following	bariatric	surgery	is	higher	in	people	with	pre-exisAng	diabetes	compared	to	those	without.
The	Emerging	Risk	Factors	CollaboraAon	study	including	123,205	deaths	among	820,900	people	found	that
people	with	diabetes	have	70%	higher	risk	of	death	from	any	cause	compared	to	those	without.18	Our	study
supports	a	similar	hypothesis	whereby	people	with	diabetes	who	undergo	bariatric	surgery	are	sAll	at	higher
risk	of	all-cause	mortality	and	other	outcomes	compared	to	those	without	diabetes,	despite	similar	short-term
mortality	and	biochemical	and	anthropometric	improvements	which	take	place	bariatric	surgery.4		Therefore,
people	with	diabetes	who	undergo	bariatric	surgery	may	need	closer	monitoring,	well-beyond	the	ﬁrst	year
post-surgery.
Currently,	there	are	no	studies	comparing	long-term	mortality	and	CVD	outcomes	following	bariatric	surgery
between	people	with	and	without	pre-exisAng	diabetes.	Nevertheless,	data	from	SICOB	including	34	deaths
within	the	ﬁrst	60	days	following	13,431	bariatric	surgery	procedures	found	a	signiﬁcant	diﬀerence	between	the
mortality	proporAons	by	diabetes	status,	i.e.	0.4%	of	parAcipants	without	diabetes	died	within	the	ﬁrst	60	days
compared	with	0.8%	parAcipants	with	diabetes.12	One	potenAal	explanaAon	of	our	ﬁndings	could	be	a	higher
number	of	exisAng	comorbidiAes	in	people	with	diabetes	as	the	risk	of	mortality	a]er	adjusAng	for	Charlson
comorbidity	index	was	26%.	Another	potenAal	explanaAon	could	be	metabolic	“memory”	phenomenon,
whereby	following	a	prolonged	duraAon	of	diabetes	the	complicaAons	persist	and	progress	despite	adequate
glycaemic	control.19	This	phenomenon	has	been	seen	in	many	trials	involving	paAents	with	type	2	diabetes
including	the	United	Kingdom	ProspecAve	Diabetes	Study	(UKPDS)20	and	several	other	studies.21-23	The	degree
of	weight	loss	is	known	to	be	the	major	driver	for	improvements	in	cardiovascular	risk	factors24,25	as	well	as
glycaemic	improvement.26	A	study	using	data	from	3,193	paAents	with	gastric	bypass	from	Virginia
Commonwealth	University	Medical	Center	found	that	a]er	one	year	of	surgery	people	with	diabetes	had
signiﬁcantly	lower	weight	loss	and	higher	BMI	compared	to	people	without	diabetes,27	which	may	potenAally
explain	why	people	with	diabetes	in	our	study	have	worse	outcomes	than	people	without	diabetes.	A	study
including	232	morbidly	obese	paAents	with	type	2	diabetes	found	the	mortality	rate	in	morbidly	obese	non-
operated	people	with	type	2	diabetes	to	be	28%.28	In	comparison,	crude	all-cause	mortality	in	the	diabetes
group	undergoing	bariatric	surgery	in	our	study	was	3.19%.	Therefore,	although	the	rate	of	all-cause	mortality
a]er	bariatric	surgery	in	people	with	type	2	diabetes	is	signiﬁcantly	higher	than	the	general	populaAon,	the	rate
is	considerably	lower	in	relaAon	to	non-operated	obese	type	2	paAents.
	
Conclusion
Using	the	largest	populaAon-based	cohort	of	bariatric	surgery	paAents	to	date,	we	found	that	despite	the
reported	improvements	in	biomarkers	and	outcomes	a]er	surgery,	and	no	signiﬁcant	diﬀerence	in	30-day
mortality	between	people	with	and	without	diabetes,	people	with	diabetes	carry	a	residual	risk	of	adverse	CVD
outcomes	and	mortality,	suggesAng	that	paAents	with	pre-exisAng	diabetes	may	need	closer	monitoring	and
risk	factor	control	in	clinical	care	following	bariatric	surgery;	further	studies	should	explore	the	potenAal
reasons	for	this	excessive	risk	in	people	with	diabetes.	Moreover,	based	on	our	ﬁndings,	paAents	with	pre-
exisAng	diabetes	undergoing	bariatric	surgery	should	be	made	aware	of	such	residual	risk	before	the	procedure
as	well	as	in	paAents	without	diabetes	it	should	be	recognised	that	the	risk	of	death	a]er	surgery	remains
higher	compared	to	subjects	from	the	general	populaAon.
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FIGURE	LEGENDS
Figure	1	-	Kaplan	Meier	plots	for	all	outcomes	comparing	people	with	and	without	diabetes
Blue,	solid	line:	without	diabetes;	Red,	doied	line:	with	diabetes.	Log-rank	test	p<0.001	for	all	outcomes.
	
Figure	2	-	Mul=variable	hazard	ra=o	comparing	mortality	and	other	outcomes	in	people	with	and	without
diabetes	aXer	bariatric	surgery
EsAmates	adjusted	for	age,	sex,	IMD	score,	ethnicity,	region,	modiﬁed	Charlson	Index	and	procedure	type.
	
Figure	3	-	Age-speciﬁc	and	age-standardised	rate	ra=o	for	all-cause	mortality	following	bariatric	surgery	in
people	with	and	without	diabetes	compared	to	the	general	popula=on
Mortality	rate	raAos	following	bariatric	surgery	in	paAents	with	(full	red	squares)	and	without	(empty	blue
squares)	pre-exisAng	diabetes	compared	to	the	general	populaAon	(England	and	Wales,	2015).
Table	1	-	Characteris+cs	of	the	study	popula+on	by	diabetes	status
	
	 	 Overall 	 No	Diabetes 	 Diabetes
	 	 N	=	35,887 % 	 n	=	26,712 % 	 n	=	9,175 %
Age	in	years† 	 	 	 	 	 	 	 	 	
<20 	 159 0.4 	 143 0.5 	 10+	ǂ ǂ
20-29 	 3,082 8.6 	 2,814 10.5 	 268 2.9
30-39 	 8,165 22.8 	 6,903 25.8 	 1,262 13.8
40-49 	 12,764 35.6 	 9,519 35.6 	 3,245 35.4
50-59 	 9,007 25.1 	 5,815 21.8 	 3,192 34.8
60-69 	 2,605 7.3 	 1,459 5.5 	 1,146 12.5
70-79 	 100+	ǂ ǂ 	 50+	ǂ ǂ 	 45 0.5
≥80 	 ǂ ǂ 	 ǂ ǂ 	 ǂ ǂ
Sex† 	 	 	 	 	 	 	 	 	
Male 	 8,070 22.5 	 5,145 19.3 	 2,925 31.9
Female 	 27,817 77.5 	 21,567 80.7 	 6,250 68.1
IMD	Score† 	 	 	 	 	 	 	 	 	
Quin=le	1	(most	deprived) 	 11,132 31.0 	 8,445 31.6 	 2,687 29.3
Quin=le	2 	 8,930 24.9 	 6,661 24.9 	 2,269 24.7
Quin=le	3 	 6,684 18.6 	 4,873 18.2 	 1,811 19.7
Quin=le	4 	 5,245 14.6 	 3,819 14.3 	 1,426 15.5
Quin=le	5	(least	deprived) 	 3,815 10.6 	 2,846 10.7 	 969 10.6
Unknown/missing 	 81 0.2 	 68 0.3 	 12 0.1
Ethnicity† 	 	 	 	 	 	 	 	 	
White 	 25,834 72.0 	 19,032 71.3 	 6,802 74.1
Asian	or	Asian	Bri=sh 	 728 2.0 	 470 1.8 	 258 2.8
Black	or	Black	Bri=sh 	 1,458 4.1 	 1,111 4.2 	 347 3.8
Mixed 	 342 1.0 	 264 1.0 	 78 0.9
Other	Ethnic	Group 	 494 1.4 	 361 1.4 	 133 1.5
Unknown 	 7,031 19.6 	 5,474 20.5 	 1,557 17.0
Region† 	 	 	 	 	 	 	 	 	
North	East 	 3,579 10.0 	 2,662 10.0 	 917 10.0
North	West 	 2,316 6.5 	 1,915 7.2 	 401 4.4
Yorkshire	&	Humber 	 4,745 13.2 	 3,770 14.1 	 975 10.6
East	Midlands 	 2,679 7.5 	 2,050 7.7 	 629 6.9
West	Midlands 	 3,599 10.0 	 2,503 9.4 	 1,096 11.9
East	of	England 	 2,082 5.8 	 1,282 4.8 	 800 8.7
London 	 8,334 23.2 	 6,352 23.8 	 1,982 21.6
South	East 	 5,393 15.0 	 3,925 14.7 	 1,468 16.0
South	West 	 3,090 8.6 	 2,192 8.2 	 898 9.8
Unknown 	 70 0.2 	 61 0.2 	 9 0.1
Charlson	Comorbidity	Score† 	 	 	 	 	 	 	 	 	
0 	 28617 79.7 	 21775 81.5 	 6842 74.6
1	to	4 	 6451 18.0 	 4504 16.9 	 1947 21.2
5+ 	 819 2.3 	 433 1.6 	 386 4.2
Procedure	Type† 	 	 	 	 	 	 	 	 	
Gastric	Bypass 	 18,437 51.4 	 13,374 50.1 	 5,063 55.2
Gastric	Banding 	 8,259 23.0 	 6,431 24.1 	 1,828 19.9
Sleeve	Gastrectomy 	 5,809 16.2 	 4,429 16.6 	 1,380 15.0
Gastroplasty 	 3,382 9.4 	 2,478 9.3 	 904 9.9
Year	of	Surgery† 	 	 	 	 	 	 	 	 	
2006	-	2010 	 17,100 47.7 	 13,276 49.7 	 3,824 41.7
2011	-2014 	 18,787 52.4 	 13,436 50.3 	 5,351 58.3
	
†	p-value	for	comparison	between	people	with	and	without	diabetes	<0.01
ǂ	one	cell	with	<5	value
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 Figure 1 - Kaplan Meier plots for all outcomes comparing people with and without diabetes 
Blue, solid line: without diabetes; Red, dotted line: with diabetes. Log-rank test p<0.001 for all outcomes. 
192x222mm (72 x 72 DPI)
 Figure 2 - Multivariable hazard ratio comparing mortality and other outcomes in people with and without diabetes after
bariatric surgery 
Estimates adjusted for age, sex, IMD score, ethnicity, region, modified Charlson Index and procedure type. 
1057x320mm (72 x 72 DPI)
 Figure 3 - Age-specific and age-standardised rate ratio for all-cause mortality following bariatric surgery in people with
and without diabetes compared to the general population 
Mortality rate ratios following bariatric surgery in patients with (full red squares) and without (empty blue squares) pre-
existing diabetes compared to the general population (England and Wales, 2015). 
890x932mm (72 x 72 DPI)
Supplementary Material 
 
Cardiovascular, cancer and mortality events after bariatric surgery 
in people with and without pre-existing diabetes:  
A nationwide study  
Nafeesa N Dhalwani1, Francesco Zaccardi1, Hina Waheed2, Jemma Mytton2, Dimitris Papamargaritis1, 
David Webb1, Felicity Evison2, Richard Lilford3, Melanie J Davies1,4, Kamlesh Khunti1  
 
 
1Diabetes Research Centre, University of Leicester, UK 
2University Hospitals Birmingham, UK 
3University of Warwick, UK 
4Leicester Biomedical Research Centre, UK 
 
  
Supplementary Table S1 - Classification for OPCS-4 Codes for bariatric surgery 
Exclusive 
G284 - Sleeve gastrectomy and duodenal switch 
G285 - Sleeve gastrectomy NEC 
G303 - Partitioning of stomach using band 
G716 - Duodenal switch 
G304 - Partitioning of stomach using staples 
G321 - Bypass of stomach by anastomosis of stomach to transposed jejunum 
G301 - Gastroplasty NEC 
G320 - Conversion from previous anastomosis of stomach to transposed jejunum 
G322 - Revision of anastomosis of stomach to transposed jejunum 
G323 - Conversion to anastomosis of stomach to transposed jejunum 
 
Non exclusive 
G312 - Bypass of stomach by anastomosis of stomach to duodenum 
G331 - Bypass of stomach by anastomosis of stomach to jejunum NEC 
G281 - Partial gastrectomy and anastomosis of stomach to duodenum 
G282 - Partial gastrectomy and anastomosis of stomach to transposed jejunum 
G283 - Partial gastrectomy and anastomosis of stomach to jejunum NEC 
G302 - Partitioning of stomach NEC 
G310 - Conversion from previous anastomosis of stomach to duodenum 
G313 - Revision of anastomosis of stomach to duodenum 
G314 - Conversion to anastomosis of stomach to duodenum 
G330 - Conversion from previous anastomosis of stomach to jejunum NEC 
G332 - Revision of anastomosis of stomach to jejunum NEC 
G333 - Conversion to anastomosis of stomach to jejunum NEC 
G335 - Closure of connection of stomach to jejunum NEC 
G336 - Attention to connection of stomach to jejunum 
G324 - Closure of connection of stomach to transposed jejunum 
G325 - Attention to connection of stomach to transposed jejunum 
 
Primary operation 
G284 - Sleeve gastrectomy and duodenal switch 
G285 - Sleeve gastrectomy NEC 
G303 - Partitioning of stomach using band 
G716 - Duodenal switch 
G304 - Partitioning of stomach using staples 
G321 - Bypass of stomach by anastomosis of stomach to transposed jejunum 
G301 - Gastroplasty NEC 
G312 - Bypass of stomach by anastomosis of stomach to duodenum 
G331 - Bypass of stomach by anastomosis of stomach to jejunum NEC 
G281 - Partial gastrectomy and anastomosis of stomach to duodenum 
G282 - Partial gastrectomy and anastomosis of stomach to transposed jejunum 
G283 - Partial gastrectomy and anastomosis of stomach to jejunum NEC 
G302 - Partitioning of stomach NEC 
 
Revision/Secondary operation 
G310 - Conversion from previous anastomosis of stomach to duodenum 
G313 - Revision of anastomosis of stomach to duodenum 
G314 - Conversion to anastomosis of stomach to duodenum 
G320 - Conversion from previous anastomosis of stomach to transposed jejunum 
G322 - Revision of anastomosis of stomach to transposed jejunum 
G323 - Conversion to anastomosis of stomach to transposed jejunum 
G330 - Conversion from previous anastomosis of stomach to jejunum NEC 
G332 - Revision of anastomosis of stomach to jejunum NEC 
G333 - Conversion to anastomosis of stomach to jejunum NEC 
G335 - Closure of connection of stomach to jejunum NEC 
G336 - Attention to connection of stomach to jejunum 
G324 - Closure of connection of stomach to transposed jejunum 
G325 - Attention to connection of stomach to transposed jejunum 
Supplementary Table S2 - ICD-10 codes for exposures and outcomes 
Conditions ICD-10 Codes 
Myocardial Infarction I21-I22, I25.2, 125.6 
Unstable Angina I20.0 
Stroke I60-I63 
Heart failure I11.0, I13.0, I13.2, I25.5, I42.0, I42.9, I50.0, I50.1, I50.9 
Cancer C00-C99 
Diabetes E10-E14 
 
Supplementary Table S3 - Number of patients identified through each code and 
category 
Codes Category No Diabetes Diabetes 
G281 - Partial gastrectomy and anastomosis of stomach to duodenum ByP 8 * 
G282 - Partial gastrectomy and anastomosis of stomach to transposed jejunum ByP 183 64 
G283 - Partial gastrectomy and anastomosis of stomach to jejunum NEC ByP 71 25 
G284 - Sleeve gastrectomy and duodenal switch ByP 49 11 
G285 - Sleeve gastrectomy NEC SG 4429 1,380 
G301 - Gastroplasty NEC GPl 322 119 
G302 - Partitioning of stomach NEC GPl 414 115 
G303 - Partitioning of stomach using band GB 6,431 1,828 
G304 - Partitioning of stomach using staples GPl 1,742 670 
G310 - Conversion from previous anastomosis of stomach to duodenum ByP 6 * 
G312 - Bypass of stomach by anastomosis of stomach to duodenum ByP 93 41 
G313 - Revision of anastomosis of stomach to duodenum ByP * * 
G314 - Conversion to anastomosis of stomach to duodenum ByP * 0 
G320 - Conversion from previous anastomosis of stomach to transposed jejunum ByP - - 
G321 - Bypass of stomach by anastomosis of stomach to transposed jejunum ByP 5,119 2,031 
G322 - Revision of anastomosis of stomach to transposed jejunum ByP 16 * 
G323 - Conversion to anastomosis of stomach to transposed jejunum ByP * * 
G324 - Closure of connection of stomach to transposed jejunum ByP * * 
G325 - Attention to connection of stomach to transposed jejunum ByP * 0 
G330 - Conversion from previous anastomosis of stomach to jejunum NEC ByP - - 
G331 - Bypass of stomach by anastomosis of stomach to jejunum NEC ByP 7,756 2,869 
G332 - Revision of anastomosis of stomach to jejunum NEC ByP 28 6 
G333 - Conversion to anastomosis of stomach to jejunum NEC ByP 13 * 
G335 - Closure of connection of stomach to jejunum NEC ByP * * 
G336 - Attention to connection of stomach to jejunum ByP * 0 
G716 - Duodenal switch ByP 16 * 
Total  26,712 9,175 
 
ByP=Bypass procedures, GPl=Gastroplasty, SG = Sleeve Gastrectomy, GB=Gastric Banding 
* number <5
Supplementary Table S4 - Multivariable cox proportional hazards regression models comparing mortality and other 
outcomes by diabetes status after bariatric surgery 
  All-cause  
mortality 
Myocardial 
Infarction 
Unstable 
Angina  
Stroke Heart failure Cancer 
Using only exclusive bariatric surgery codes 
Hazard Ratio (95% CI)* 1.33 (1.10-1.60) 1.66 (1.08-2.56)b 1.83 (1.24-2.46) 1.70 (1.18-2.46)c 1.63 (1.26-2.11)d 1.30 (1.11-1.51)e 
Using only primary bariatric surgery codes 
Hazard Ratio (95% CI)* 1.26 (1.08-1.47) 2.08 (1.42-3.04)b 1.80 (1.29-2.51) 1.58 (1.16-2.15)c 1.41 (1.13-1.75)d 1.22 (1.07-1.38)e 
 
*Using people without diabetes as a reference, adjusted for age, sex, IMD score, ethnicity, region, procedure type, b additionally excluding MI from Charlson index, c additionally excluding stroke 
from Charlson index, d additionally excluding heart failure from Charlson index e additionally excluding cancer from Charlson index 
Supplementary Figure S1 - Incidence rates (95% CI) for all outcomes following bariatric surgery in people with 
and without diabetes 
 
 
Supplementary Figure S2 - Age-specific mortality rates in the general population, compared to people with and 
without diabetes 
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Cardiovascular, cancer and mortality events after bariatric surgery in people with and 
without pre-existing diabetes: A nationwide study 
 
 Item No Recommendation Page 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or 
the abstract 
1 
(b) Provide in the abstract an informative and balanced summary of what 
was done and what was found 
1 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being 
reported 
3 
Objectives 3 State specific objectives, including any prespecified hypotheses  3 
Methods  
Study design 4 Present key elements of study design early in the paper  4 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
 4 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection 
of participants. Describe methods of follow-up 
 4 
(b) For matched studies, give matching criteria and number of exposed 
and unexposed 
NA 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, 
and effect modifiers. Give diagnostic criteria, if applicable 
 4-5 
Data sources/ 
measurement 
8* For each variable of interest, give sources of data and details of methods 
of assessment (measurement). Describe comparability of assessment 
methods if there is more than one group 
 4-5 
Bias 9 Describe any efforts to address potential sources of bias  5-6 
Study size 10 Explain how the study size was arrived at  7 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why 
 5 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for 
confounding 
 5 
(b) Describe any methods used to examine subgroups and interactions  5 
(c) Explain how missing data were addressed  5 
(d) If applicable, explain how loss to follow-up was addressed NA 
(e) Describe any sensitivity analyses 5-6 
Results  
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included 
in the study, completing follow-up, and analysed 
 7 
(b) Give reasons for non-participation at each stage  7 
(c) Consider use of a flow diagram - 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, 
social) and information on exposures and potential confounders 
 7 
(b) Indicate number of participants with missing data for each variable of 
interest 
 7 
 2 
(c) Summarise follow-up time (eg, average and total amount)  7 
Outcome data 15* Report numbers of outcome events or summary measures over time  7-8 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included 
 7-8 
(b) Report category boundaries when continuous variables were 
categorized 
NA 
(c) If relevant, consider translating estimates of relative risk into absolute 
risk for a meaningful time period 
- 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, 
and sensitivity analyses 
 9 
Discussion  
Key results 18 Summarise key results with reference to study objectives  10 
Limitations 19 Discuss limitations of the study, taking into account sources of potential 
bias or imprecision. Discuss both direction and magnitude of any potential 
bias 
 10-11 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence 
 11-12 
Generalisability 21 Discuss the generalisability (external validity) of the study results  12-13 
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study 
and, if applicable, for the original study on which the present article is 
based 
14 
 
*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at http://www.strobe-statement.org. 
 
